Drug interactions
Atogepant + Liposomal doxorubicin
Severity: Minor
Atogepant and Liposomal doxorubicin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Doxorubicin is described as a CYP3A4 inhibitor in some databases, which would raise atogepant exposure. In practice, liposomal doxorubicin has no established clinically relevant CYP3A4 inhibition. A meaningful interaction is unlikely.
What this interaction means in plain words
Atogepant and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Atogepant belongs to Central Nervous System; Liposomal doxorubicin belongs to Oncology.
Why it happens
Theoretical CYP3A4 inhibition by doxorubicin may slightly raise atogepant levels; not clinically established.
What to do
No adjustment is needed; monitor for atogepant adverse effects such as nausea and constipation.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Atogepant and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Atogepant
- Amobarbital + Atogepant Moderate
- Apalutamide + Atogepant Moderate
- Aprepitant + Atogepant Moderate
- Armodafinil + Atogepant Moderate
- Atogepant + Bosentan Moderate
- Atogepant + Carbamazepine Moderate
Frequently asked questions
Can I take Atogepant with Liposomal doxorubicin?
MediHelp rates the interaction as minor. Atogepant and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Doxorubicin is described as a CYP3A4 inhibitor in some databases, which would raise atogepant exposure. In practice, liposomal doxorubicin has no established clinically relevant CYP3A4 inhibition. A meaningful interaction is unlikely.
How serious is the interaction between Atogepant and Liposomal doxorubicin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No adjustment is needed; monitor for atogepant adverse effects such as nausea and constipation.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
